This aligns with the ARTS-HF trial (60, 61) published in 2016, which suggested that finerenone's selective MR modulation could block harmful gene activation even in the absence of aldosterone and may offer advantages over steroidal MRAs (62). This evidence concerns the gene NR3C2 and hydrops fetalis.